Imperial College London
Portrait Picture

Dr Hannah M Cheeseman

Faculty of Medicine, Department of Infectious Disease

Postdoctoral Researcher & Clinical Trials Laboratory Manager
 
 
 
//

Contact

 

+44 (0)20 7594 2540hannah.cheeseman

 
 
//

Location

 

452 - Shattock GroupNorfolk PlaceSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Hayes:2013:10.1128/CVI.00637-12,
author = {Hayes, P and Gilmour, J and von, Lieven A and Gill, D and Clark, L and Kopycinski, J and Cheeseman, H and Chung, A and Alter, G and Dally, L and Zachariah, D and Lombardo, A and Ackland, J and Sayeed, E and Jackson, A and Boffito, M and Gazzard, B and Fast, PE and Cox, JH and Laufer, D},
doi = {10.1128/CVI.00637-12},
journal = {Clin Vaccine Immunol},
pages = {397--408},
title = {Safety and immunogenicity of DNA prime and modified vaccinia ankara virus-HIV subtype C vaccine boost in healthy adults.},
url = {http://dx.doi.org/10.1128/CVI.00637-12},
volume = {20},
year = {2013}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - A randomized, double-blind, placebo-controlled phase I trial was conducted in 32 HIV-uninfected healthy volunteers to assess the safety and immunogenicity of 3 doses of DNA vaccine (Advax) plus 1 dose of recombinant modified vaccinia virus Ankara (MVA) (TBC-M4) or 3 doses of TBC-M4 alone (groups A and B, respectively). Both vaccine regimens were found to be safe and well tolerated. Gamma interferon (IFN-γ) enzyme-linked immunosorbent spot (ELISPOT) assay responses were detected in 1/10 (10%) individuals in group A after three Advax primes and in 9/9 individuals (100%) after the MVA boost. In group B, IFN-γ ELISPOT responses were detected in 6/12 (50%) and 7/11 (64%) individuals after the second and third MVA vaccinations, respectively. Responses to all vaccine components, but predominantly to Env, were seen. The breadth and magnitude of the T cell response and viral inhibition were greater in group A than in group B, indicating that the quality of the T-cell response was enhanced by the DNA prime. Intracellular cytokine staining indicated that the T-cell responses were polyfunctional but were skewed toward Env with a CD4(+) phenotype. At 2 weeks after the last vaccination, HIV-specific antibody responses were detected in all (100%) group B and 1/11 (9.1%) group A vaccinees. Vaccinia virus-specific responses were detected in all (100%) group B and 2/11 (18.2%) group A vaccinees. In conclusion, HIV-specific T-cell responses were seen in the majority of volunteers in groups A and B but with a trend toward greater quality of the T-cell response in group A. Antibody responses were better in group B than in group A.
AU  - Hayes,P
AU  - Gilmour,J
AU  - von,Lieven A
AU  - Gill,D
AU  - Clark,L
AU  - Kopycinski,J
AU  - Cheeseman,H
AU  - Chung,A
AU  - Alter,G
AU  - Dally,L
AU  - Zachariah,D
AU  - Lombardo,A
AU  - Ackland,J
AU  - Sayeed,E
AU  - Jackson,A
AU  - Boffito,M
AU  - Gazzard,B
AU  - Fast,PE
AU  - Cox,JH
AU  - Laufer,D
DO  - 10.1128/CVI.00637-12
EP  - 408
PY  - 2013///
SP  - 397
TI  - Safety and immunogenicity of DNA prime and modified vaccinia ankara virus-HIV subtype C vaccine boost in healthy adults.
T2  - Clin Vaccine Immunol
UR  - http://dx.doi.org/10.1128/CVI.00637-12
UR  - https://www.ncbi.nlm.nih.gov/pubmed/23345581
VL  - 20
ER  -
Download